Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2016-04-01 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on Regulation FD disclosures about upcoming presentations of clinical data posters at medical meetings. It includes references to exhibits that are posters related to clinical trial data. There are no financial statements, earnings data, management changes, or other report types typically found in annual or quarterly reports. The document is relatively short (3095 characters) and serves as an announcement of events and exhibits rather than a detailed financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-04-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text includes references to Regulation FD Disclosures and abstracts filed as exhibits related to clinical data, but it does not contain comprehensive financial statements or detailed financial analysis. The document length is 2567 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. The document is primarily an announcement of clinical data abstracts and related exhibits, fitting the category of a Regulatory Filing (RNS) as a general SEC filing that does not fit other specific categories.
2016-03-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The content includes announcements of press releases about clinical data presentations at conferences, filed as exhibits. There are no financial statements or detailed financial data included. The document is relatively short (2563 characters) and primarily serves as a regulatory announcement of events and press releases. It does not contain an annual report, earnings release, or detailed financial or management information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-03-28 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 11, 2016, by Lipocine Inc. It announces that the company will be presenting materials at the 28th Annual Roth Conference on March 13-16, 2016. The document includes references to attached exhibits which are presentations for investors. The key section is Item 7.01 Regulation FD Disclosures, which typically covers investor presentations or similar disclosures. The document does not contain financial statements or detailed financial analysis itself but rather announces and attaches presentation materials. Given the nature of the content—presentation materials for investors at a conference—the most appropriate classification is Investor Presentation (IP). The document length is short and it is not a full financial report or earnings release. Therefore, the classification is IP with high confidence.
2016-03-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 10, 2016, by Lipocine Inc. It reports the issuance of a press release announcing financial and operational results for the year ended December 31, 2015. The document itself does not contain the financial results but references a press release (Exhibit 99.1) that contains the results. The length of the document is 2330 characters, which is short and primarily serves as an announcement of the financial results release. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain substantive financial data itself.
2016-03-10 English
10-K
Annual Report FY 2015
2016-03-10 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.